Type private Products NanoFuse DBM Founded 2000 | Key people James Talton CEO Founder James Talton | |
Formerly called Nanocoat Technologies (2000–2002) Industry Pharmaceutical industry Headquarters Alachua, Florida, United States | ||
Nanotherapeutics, Inc. is a private, American biopharmaceutical company headquartered in Alachua, Florida. The company uses nanometer-scale particle technology in developing new drugs and in increasing the efficacy of existing drugs.
Contents
History
Nanotherapeutics is a product of the Sid Martin Biotechnology Incubator of Alachua, Florida. It was established in 2000 as Nanocoat Technologies by James Talton. The company took its present name in 2002.
At the end of 2014, Baxter indicated its intention to sell a vaccine production technology based on Vero cell culture to Nanotherapeutics; this was to include developed vaccines for H5N1, H1N1 and seasonal influenza, as well as a number of investigational vaccine programs.
Business model
Nanotherapeutics product development is based on utilization of nanometer-scale particle technology. This places at least some of its products in the category of medical devices, such as NanoFuse DBM, approval of which can take advantage of the FDA 510(k) expedited review route.
The company has a history of securing United States government grants and contracts, in particular through the Department of Defense, as a source of revenue.
Like many other companies, Nanotherapeutics has secured venture capital funding, and entered into product co-development alliances.
Operations
The company headquarters are located in the office park housing the Sid Martin Biotechnology Incubator in Alachua, Florida. In 2013, the company had 45 employees and was working with the University of Florida Foundation to construct a new manufacturing facility in close proximity to the company headquarters.
In late-2014, the company opened an office in Frederick, Maryland to have a presence in close proximity to United States government agencies with which it frequently contracts. At the end of 2014, the company intended to acquired from Baxter a vaccine manufacturing facility in the Czech Republic.